Boehringer re­ports ro­bust sales led by type 2 di­a­betes and pul­monary drugs, promis­es more to come high­light­ing obe­si­ty

Boehringer In­gel­heim re­port­ed hu­man phar­ma sales of €18.5 bil­lion on Wednes­day, led by type 2 di­a­betes and heart fail­ure drug Jar­diance and pul­monary fi­bro­sis med Ofev. Jar­diance sales reached €5.8 bil­lion, grow­ing 39% year over year, while Ofev took in €3.2 bil­lion, notch­ing its own 20.6% an­nu­al jump.

How­ev­er, Boehringer is al­so look­ing ahead with its pipeline, es­ti­mat­ing “In the next sev­en years the com­pa­ny ex­pects about 20 reg­u­la­to­ry ap­provals in hu­man phar­ma.”

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN